Fujirebio and Eisai Partner to Advance Diagnostics for Neurodegenerative Diseases

European Commission Approves Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H or dMMR mCRC

Deerfield Management to Acquire Singular Genomics for $20 Per Share in All-Cash Deal

EU Approval of Tagrisso Sets New Standard for EGFR-Mutated NSCLC Treatment

Aurobindo Pharma’s Subsidiary CuraTeQ Secures UK Approval for Bevacizumab Biosimilar

SCG Cell Therapy Partners with A*STAR BTI and NATi to Advance RNA-Based Therapeutics

Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

Home
/
update
/
details

Amgen Unveils New Technology and Innovation Hub in Hyderabad

NextEdge Admin

09 Aug 2024

2 min 5 sec

Amgen, a global biotechnology leader, is set to establish a new technology and innovation site in Hyderabad, marking a significant step in its global expansion strategy. Named Amgen India, the site will open in the fourth quarter of 2024 in Hitech City, spanning six floors and accommodating up to 3,000 employees.

Hyderabad was chosen for its renowned talent pool in medicine, life sciences, data sciences, and its advancing AI sector. The new facility will bolster Amgen’s digital capabilities, accelerating the development of innovative medicines. David M. Reese, M.D., Executive Vice President and Chief Technology Officer at Amgen, emphasized the strategic importance of this expansion, noting that the convergence of biotechnology and technology enables Amgen to operate with greater speed and efficiency.

Amgen India will focus initially on AI, data science, and life sciences, with plans to scale its global capabilities. Som Chattopadhyay has been appointed as the national executive to lead this expansion.

Telangana Chief Minister A. Revanth Reddy and Industries Minister Duddilla Sridhar Babu expressed pride in Hyderabad’s selection, highlighting the city's growing reputation as a life sciences hub. They emphasized the government’s commitment to partnering with Amgen for long-term success.

This new site strengthens Amgen’s global presence, furthering its mission to serve patients through innovation in biotechnology.